<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837367</url>
  </required_header>
  <id_info>
    <org_study_id>UniversityMedPharmaVBT</org_study_id>
    <nct_id>NCT02837367</nct_id>
  </id_info>
  <brief_title>Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People</brief_title>
  <acronym>NutriGen</acronym>
  <official_title>Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Pharmacy &quot;Victor Babes&quot; Timisoara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Romania:The National Authority for Scientific Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Medicine and Pharmacy &quot;Victor Babes&quot; Timisoara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NutriGen project will be using nutrigenomic methods to determine the effectiveness of
      treatments with specific dietary foods, on the basis of genetic risk predisposition (genetic
      signature) of obese individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NutriGen project specific aim 1. Establishing a genetic signature model, involved in the
      donation of methyl groups and unsaturated omega-6/3 fatty acids metabolism, with a high
      predictive value for classification of dyslipidemia and insulin resistance in obese subjects.

        1. Establishing a genetic signature model in obese adults with dyslipidemia.

        2. Establishing a genetic signature model in obese children with insulin resistance. c.
           Establishing a correlation between blood/plasma concentrations of the relevant
           metabolites, genetic signatures and dyslipidemia profile of adults, and respectively a
           profile for insulin resistance in obese children.

      NutriGen project specific aim 2. Determining the efficacy of a dietary food specific
      treatment, which is also correlated with a genetic signature (nutrigenomics), based on the
      correlations defined in objective 1:

        1. Implementation of a treatment with dietary foods (for adults), in the presence/absence
           of other already prescribed treatments;

        2. Implementation of a treatment with dietary foods (for children), in the presence/absence
           of other already prescribed treatments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>3 years</time_frame>
    <description>HDL-cholesterol (HDLc), LDL-cholesterol (LDLc), triglycerides (TG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>3 years</time_frame>
    <description>HOMA-IR</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Obesity</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Adult intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention will consist of the administration of nutrients (as capsules) containing: 2 g betaine, 800 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 1000 ug (micrograms) Vitamin B12, 500 mg choline bitartrate, 1 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 280 mg DHA (docosahexaenoic acid).
Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The intervention will consist of the administration of nutrients (as capsules) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).
Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention will consist of the administration of nutrients (as capsules) containing: 1 g betaine, 400 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 500 ug (micrograms) Vitamin B12, 250 mg choline bitartrate, 0.5 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 140 mg DHA (docosahexaenoic acid).
Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The intervention will consist of the administration of nutrients (as capsules) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).
Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults genetic assessment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in adult people with obesity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children genetic assessment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in children with obesity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic modeling</intervention_name>
    <arm_group_label>Adults genetic assessment</arm_group_label>
    <arm_group_label>Children genetic assessment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Administration of supplements containing methyl-donors</intervention_name>
    <arm_group_label>Adult intervention</arm_group_label>
    <arm_group_label>Adult placebo</arm_group_label>
    <arm_group_label>Children intervention</arm_group_label>
    <arm_group_label>Children Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults: between 18 and 70 years old; obesity present as defined by body mass index
             (BMI) ≥30 kg/m2 and by abdominal circumference ≥84 cm (women), and ≥90 cm (men);
             dyslipidemia present as defined by: serum Cholesterol ≥200 mg/dl, HDLc ≤50 mg/dl
             (women) or ≤40 mg/dl (men), serum Triglycerides ≥150 mg/dl, or present treatment for
             dyslipidemia (e.g. statins, fibrates, omega-3 fatty acids, cholestyramine, ezetimibe).

          -  Children: age between 7 and 18 years old; BMI &gt;+2SD WHO reference

        Exclusion Criteria:

          -  Adults: diagnosed for any type of cancer, or medical history of cancer; any
             auto-immune disease; any psychiatric disorder; blood coagulation disorders; history of
             drug abuse; alcohol abuse evaluated using AUDIT-C.

          -  Children: the above exclusion criteria for adults; familial hypercholesterolemia;
             endocrine-induced obesity (Cushing syndrome, hypothyroidism, growth hormone deficit),
             hypothalamus-induced obesity (Babinski-Fröhlich syndrome), genetic syndromes
             (Prader-Willi, achondroplasia, Bardet-Biedl, Fanconi, Turner, etc.); deposition
             diseases (glycogenosis, lipomatosis); personal history for: convulsive disorders,
             nephrotic syndrome, or asthma that necessitated corticoid treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mihai Niculescu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Medicine and Pharmacy &quot;Victor Babes&quot; Timisoara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Puiu, MD, PhD</last_name>
    <phone>0040730118152</phone>
    <email>maria_puiu@umft.ro</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinica II Pediatrie Bega</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iulian Velea, MD, PhD</last_name>
      <phone>0771522781</phone>
      <email>ivelea@umft.ro</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean Timisoara; Centrul de Diabet</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Sima, MD, PhD</last_name>
      <phone>0770727169</phone>
      <email>alexa_moisuc@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <reference>
    <citation>Corbin KD, Abdelmalek MF, Spencer MD, da Costa KA, Galanko JA, Sha W, Suzuki A, Guy CD, Cardona DM, Torquati A, Diehl AM, Zeisel SH. Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis. FASEB J. 2013 Apr;27(4):1674-89. doi: 10.1096/fj.12-219097. Epub 2013 Jan 4.</citation>
    <PMID>23292069</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Medicine and Pharmacy &quot;Victor Babes&quot; Timisoara</investigator_affiliation>
    <investigator_full_name>Maria Puiu</investigator_full_name>
    <investigator_title>Professor Dr Maria Puiu</investigator_title>
  </responsible_party>
  <keyword>nutrigenetics</keyword>
  <keyword>medical foods</keyword>
  <keyword>obesity</keyword>
  <keyword>children</keyword>
  <keyword>adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

